Moderna says individualized mRNA melanoma therapy met Phase 3 endpoints

Moderna and Merck announced positive Phase 3 results for intismeran autogene, an individualized mRNA therapy used with Keytruda after complete resection of stage IIB-IV melanoma. Moderna said the study met its primary recurrence-free-survival endpoint and a key secondary endpoint for distant metastasis-free survival. The company described the result as the first positive Phase 3 outcome for an individualized neoantigen therapy and for an mRNA-based cancer therapy.